Breathe New Life into Your Surplus
Asset Management Program

Biopharmaceuticals companies must keep pace with increasingly tough competition, expand into new global markets, and continually improve efficiency and grow working capital. Liquidity Services’ expert reverse supply chain solutions help you extract maximum value from your surplus and idle assets, fueling your strategic initiatives and allowing you to focus on core business.
Contact Us

NEARLY

5 MILLION

ASSETS SOLD

MORE THAN

$450 MILLION

IN TOTAL SALES

OVER 70,000

REGISTERED BUYERS

We Know Biopharmaceuticals

Keep Pace with Change and Focus on What Counts

As patents expire and generic brands threaten powerhouse drug manufacturers, competition is heating up like never before. To remain successful, biopharmaceuticals companies must evaluate and reinvigorate their business models. With a long history of driving success for the industry’s largest manufacturers, Liquidity Services can help you strategically use existing resources and free up capital to develop new products, expand your reach, and stay ahead of the competition.

Tap into the Global Customer Base

As globalization creates new growth markets around the world, biopharmaceuticals companies are expanding operations into new regions. With 3 million buyers in almost 200 countries and territories, we help you maximize investment recovery for your surplus assets. Liquidity Services has proven experience managing complex, global surplus programs, providing your reverse supply chain with the comprehensive support it needs, everywhere you need it.

Efficiently Produce Better Quality Outcomes

Many biopharmaceuticals companies are aiming to improve efficiency and quality by upgrading equipment, which results in surplus assets. No matter the volume, category, condition, or location of your assets, Liquidity Services can administer the entire scope of your reverse supply chain. Our dedicated industry experts operate as seamless extensions of your team to manage, value, and sell surplus assets, maximizing velocity and investment recovery.

Increase ROI on M&A

Your industry is seeing continued merger and acquisition activity, and these changes inevitably produce surplus assets. Our valuation services help identify your surplus and its market value, while our AssetZone® software allows you to make superior decisions about selling or redeploying it. And our proven marketing and sales strategies ensure you maximize investment recovery.

Stay Ahead by Staying in Compliance

New regulatory hurdles – such as rules pertaining to R&D and manufacturing equipment – have introduced further complexities to your industry. We offer a full suite of compliance and risk mitigation services, backed by a global team of experts. This ensures you are compliant with all considerations inherent to responsibly managing surplus – such as the decontamination of sensitive assets – as well as your internal policies.

500+ Asset Categories.
One Company.

Liquidity Services has expertise in nearly every biopharmaceuticals asset category:
  • Mass Spectrometers
  • High-Performance Liquid Chromatographs
  • Sequence Detectors
  • Microscopes
  • Lab Balances & Weighing
  • Microplate Readers & Washers
  • Nuclear Magnetic Resonance Devices
  • Reactors
  • Liquid Handling & Weighing
  • Plant Support Equipment
  • Spectrophotometers
More Sales Methods. Higher Recovery.